LQDA Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of -2301.55%. Liquidia Corp.'s return on equity of -221.75% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Liquidia Corp. has a consensus price target of $39.00, signalling upside risk potential of 22.94%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 43.31%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Liquidia Corp., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Liquidia Corp..

Liquidia Corp. has a beta of 0.482, which suggesting that the stock is 51.777% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $54.3M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Liquidia Corp.'s net income of -$3.5M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 44.18x versus 51.01x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of -6.8%. Liquidia Corp.'s return on equity of -221.75% beat Bruker Corp.'s return on equity of -1.2%.

Liquidia Corp. has a consensus price target of $39.00, signalling upside risk potential of 22.94%. On the other hand Bruker Corp. has an analysts' consensus of $51.79 which suggests that it could grow by 7.84%. Given that Liquidia Corp. has higher upside potential than Bruker Corp., analysts believe Liquidia Corp. is more attractive than Bruker Corp..

Liquidia Corp. has a beta of 0.482, which suggesting that the stock is 51.777% less volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.405%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.42% to investors and pays a quarterly dividend of $0.05 per share. Liquidia Corp. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Liquidia Corp. quarterly revenues are $54.3M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Liquidia Corp.'s net income of -$3.5M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 44.18x versus 2.13x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings Corp. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of 8.5%. Liquidia Corp.'s return on equity of -221.75% beat Integer Holdings Corp.'s return on equity of 5.26%.

Liquidia Corp. has a consensus price target of $39.00, signalling upside risk potential of 22.94%. On the other hand Integer Holdings Corp. has an analysts' consensus of $85.57 which suggests that it could grow by 8.72%. Given that Liquidia Corp. has higher upside potential than Integer Holdings Corp., analysts believe Liquidia Corp. is more attractive than Integer Holdings Corp..

Liquidia Corp. has a beta of 0.482, which suggesting that the stock is 51.777% less volatile than S&P 500. In comparison Integer Holdings Corp. has a beta of 0.818, suggesting its less volatile than the S&P 500 by 18.19%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Integer Holdings Corp. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $54.3M, which are smaller than Integer Holdings Corp. quarterly revenues of $466.6M. Liquidia Corp.'s net income of -$3.5M is lower than Integer Holdings Corp.'s net income of $39.7M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Integer Holdings Corp.'s PE ratio is 32.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 44.18x versus 1.52x for Integer Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of 42.36%. Liquidia Corp.'s return on equity of -221.75% beat United Therapeutics Corp.'s return on equity of 19.2%.

Liquidia Corp. has a consensus price target of $39.00, signalling upside risk potential of 22.94%. On the other hand United Therapeutics Corp. has an analysts' consensus of $518.25 which suggests that it could grow by 1.53%. Given that Liquidia Corp. has higher upside potential than United Therapeutics Corp., analysts believe Liquidia Corp. is more attractive than United Therapeutics Corp..

Liquidia Corp. has a beta of 0.482, which suggesting that the stock is 51.777% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.874%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $54.3M, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. Liquidia Corp.'s net income of -$3.5M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while United Therapeutics Corp.'s PE ratio is 19.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 44.18x versus 7.87x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.